PENTAMIDINE ISETHIONATE

Post-LOE

pentamidine isethionate

Fresenius Kabi

ANDAINJECTIONINJECTABLE

Approved

Mar 2022

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

PENTAMIDINE ISETHIONATE (pentamidine isethionate) by Fresenius Kabi is clinical pharmacology pentamidine isethionate, an aromatic diamidine, is known to have activity against pneumocystis carinii . Approved for pneumonia due to pneumocystis carinii. First approved in 2022.

Drug data last refreshed 18h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Pentamidine isethionate, an aromatic diamidine, is known to have activity against Pneumocystis carinii . The mode of action of pentamidine is not fully understood. In vitro studies indicate that the drug interferes with protozoal nuclear metabolism by inhibition of DNA, RNA,…

Worked on PENTAMIDINE ISETHIONATE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

PENTAMIDINE ISETHIONATE

Mechanism of Action

Indications (1)